Following the FDA's green light for a combo regimen of Sanofi’s Sarclisa in patients with newly diagnosed multiple myeloma ...

A new drug combination, talquetamab and teclistamab, shows promising results in treating patients with heavily pretreated ...

On Friday, Johnson & Johnson (NYSE:JNJ) released updated results from the investigational Phase 1b RedirecTT-1 study ...

Multiple myeloma (MM) is a type of blood cancer that typically has no cure. Treatments like medications and stem cell ...

Speakers on precursor disease addressed distinctions between MGUS and smoldering multiple myeloma, risk stratification, and ...

Radiotherapy had a distinct advantage over surgery in reducing myeloma progression while maintaining comparable survival ...

HDP-101, a novel antibody-drug conjugate, targets BCMA with a synthetic amanitin payload that causes tumor cell death.

Daratumumab plus VRd is a more effective frontline treatment option for patients who cannot undergo immediate transplant, ...

Multiple myeloma patients with COVID-19 have high rates of hospitalization, ICU admission, and death, according to researchers.

Multiple myeloma is a type of blood cancer that disproportionately impacts Black Americans. Here's why and what's being done.

Belantamab plus VRd led to promising outcomes in newly diagnosed transplant-eligible myeloma, study results showed.

Results for the company's Cepheus phase 3 trial showed a 60.9% improvement in eliminating cancer cells and a 43% reduction in the cancer progressing or causing death when its treatmentis used in ...